Off-label use of recombinant activated factor VII for cardiac surgical bleeding.

BC Flynn, ME Steiner, M Mazzeffi - Anesthesiology, 2023 - europepmc.org
Recombinant activated factor VII has been widely used in an off-label manner for cardiac
surgical bleeding. Recent reports have administered recombinant activated factor VII earlier …

Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia

M Mazzeffi, J Beller, R Strobel, A Norman… - … of Cardiothoracic and …, 2024 - Elsevier
Objectives To explore trends in intraoperative procoagulant factor concentrate use in
patients undergoing heart transplantation (HTx) in Virginia. Secondarily, to evaluate their …

[HTML][HTML] Cardiac Surgical Bleeding, Transfusion, and Quality Metrics: Joint Consensus Statement by the Enhanced Recovery After Surgery Cardiac Society and …

R Salenger, RC Arora, A Bracey, M D'Oria… - The Annals of Thoracic …, 2024 - Elsevier
ABSTRACT BACKGROUND Excessive perioperative bleeding is associated with major
complications in cardiac surgery, resulting in increased morbidity, mortality and cost …

Factor Eight Inhibitor Bypass Activity Use in Cardiac Surgery: A Propensity-matched Analysis of Safety Outcomes

JA Nicholas, N Harrison, D Chakraborty… - …, 2024 - ingentaconnect.com
Background Bleeding during cardiac surgery may be refractory to standard interventions. Off-
label use of factor eight inhibitor bypass activity (FEIBA) has been described to treat such …

The Year in Coagulation and Transfusion: Selected Highlights from 2022

N Guinn, K Tanaka, G Erdoes, J Kwak… - Journal of cardiothoracic …, 2023 - Elsevier
This is an annual review to cover highlights in transfusion and coagulation in patients
undergoing cardiovascular surgery. The goal of this article is to provide readers with a …